RVTY
Revvity, Inc.
Is RVTY Halal?
Life-sciences and diagnostics company — generally permissible research and healthcare tools with passing current asset ratios and disclosed low interest income.
What You Should Know
Revvity, Inc. provides reagents, instruments, software and diagnostics used in research, drug discovery and clinical testing. Its April 5, 2026 Form 10-Q reports $11,996.59 million of assets, $3,226.15 million of combined debt, $860.32 million of cash, $691.38 million of accounts receivable and $711.118 million of first-quarter revenue. Debt/assets is 26.89%, liquidity/assets is 7.17%, receivables-plus-cash/assets is 12.93% and investment income interest/revenue is 0.89%. Scientific and healthcare tools are generally permissible, while customer end uses and acquisition exposures remain incomplete.
⚠️ Concerns
- •Debt/assets is 26.89% and should be confirmed under market-cap methods
- •Receivables-plus-cash/assets is 12.93%, below the examined limits
- •Disclosed investment income interest is 0.89% of revenue; follow the chosen purification guidance
- •Life-sciences tools support mixed research, pharmaceutical and clinical workflows
- •Re-screen after acquisitions or material balance-sheet changes
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-04-05; calculated 2026-07-15.
3,226.15 / 11,996.59
860.32 / 11,996.59
1,551.7 / 11,996.59
6.304 / 711.118
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 26.89%, liquidity/assets is 7.17%, receivables plus cash/assets is 12.93% and interest income/revenue is 0.89%, below the examined limits; activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 26.89%, liquidity/assets is 7.17% and receivables plus cash/assets is 12.93%, below the examined MSCI limits; activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and liquidity/assets are below the examined Malaysia SAC limits; activity remains incomplete and this is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored, so market-cap denominator methods are not estimated from a current spot price.
Business-activity disclosure
Revvity provides life-sciences instruments, reagents, software and diagnostics used in research and clinical testing. Scientific and healthcare tools are generally permissible, while customer end uses, acquisitions and product-level exposures require continuing review.
Limitation: The filing does not allocate every research, diagnostics, customer or acquisition-related revenue stream into a universal prohibited-activity numerator.
Purification
Revvity discloses $6.304 million of investment income interest, but no scholar-approved purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are USD millions from Revvity's April 5, 2026 Form 10-Q.
- Debt uses $3,226.15 million of combined current and long-term debt; operating leases are excluded.
- Cash and cash equivalents are $860.32 million; no separate interest-bearing securities balance is added from the extracted facts.
- Accounts receivable, net is $691.38 million and first-quarter revenue is $711.118 million.
- Investment income interest is $6.304 million; the filing does not provide a universal prohibited-revenue numerator for research, diagnostics or customer end uses.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →